CRISPR plants won't be regulated
Posted by btwatson on March 29, 2018 4:40 pm
Tags:
Categories:
Crispr Articles
Source: CRISPR plants won't be regulated

In a big win for the biotech industry, the US Department of Agriculture says it won’t regulate plants whose genomes have been altered using gene-editing technology.
Why it’s a field day: The decision means that we could see a boom in newfangled plants from firms like Monsanto, universities, and startups like Calyxt, whose oil-altered soybeans featured in our cover story late last year.
What changed? Under President Obama, the USDA laid out plans to regulate genetically edited plants for safety. But the Trump administration scuttled those rules. Now the USDA says these plants pose “no risk.”
Here’s the logic: The USDA says gene editing is just a (much) faster form of breeding. So long as a genetic alteration could have been bred into a plant, it won’t be regulated. That includes changes that create immunity to disease or natural resistance to crop chemicals, as well as edits to make seeds bigger and heavier. It doesn’t include transgenic plants (those with a gene from a distant species)—those will still be regulated.
Problems ahead: Trade in major crops is a global affair. Unless Europe and China agree with the US, exports of CRISPR plants could yet be blocked.
Image credit:
- ThiloBecker | Pixababy
Published at Thu, 29 Mar 2018 15:56:34 +0000
Crispr News
-
The Download: generative AI’s carbon footprint, and a CRISPR patent battle - MIT Technology ReviewDecember 1, 2023
-
Schroder Investment Management Group Has $7.12 Million Stock ... - MarketBeatDecember 1, 2023
-
Could CRISPR Therapeutics Become the Next Vertex ... - The Motley FoolDecember 1, 2023
-
The first CRISPR cure might kickstart the next big patent battle - MIT Technology ReviewDecember 1, 2023
-
Looking for Growth? 2 Top Stocks to Buy Hand Over Fist - The Motley FoolDecember 1, 2023
-
The Zacks Analyst Blog Highlights ARK Innovation ETF, Roundhill ... - NasdaqDecember 1, 2023
-
Breakthrough in Malaria detection: new FREM platform delivers 98 ... - News-Medical.NetDecember 1, 2023
-
Experimental treatment using CRISPR to dramatically lower ... - Genetic Literacy ProjectDecember 1, 2023
-
Precise base editing without unintended indels in human cells and ... - Nature.comDecember 1, 2023
-
Could CRISPR cure HIV someday? - Livescience.comNovember 30, 2023
-
The 2 Minute Medicine Podcast Episode 29 - 2 Minute MedicineNovember 30, 2023
-
Ribosomal stalk-captured CARF-RelE ribonuclease inhibits translation following CRISPR signaling - ScienceNovember 30, 2023
-
AstraZeneca, University of Cambridge Expand Functional Genomics ... - Genetic Engineering & Biotechnology NewsNovember 30, 2023
-
New Medicines, Markets, and Manufacture: CRISPR for Sickle Cell Disease and β-thalassemia - Pharmaceutical Technology MagazineNovember 30, 2023
-
Complex synthetic lethality in cancer - Nature.comNovember 30, 2023
- CRISPR rivals put patents aside to help in fight against Covid-19 – STAT
- CRISPR 2.0: Base Editing in the Groove – Genetic Engineering & Biotechnology News
- The Promises of CRISPR Genome Editing in Biomedicine – Labiotech.eu
- The Code Breaker and Crispr People — the ethics of editing humanity – Financial Times
- ERS Genomics Licenses CRISPR Patents to CRO ZeClinics – GenomeWeb
- The Dark Side of CRISPR – Scientific American
- ERS Genomics and ZeClinics Sign CRISPR/Cas9 License Agreement – BioSpace
- Scientists Use CRISPR To Create Model of AML Progression – AJMC.com Managed Markets Network
- DECODR app identifies DNA mutations from CRISPR gene therapies – European Pharmaceutical Review
- CRISPR/Cas technology as a promising weapon to combat viral infections – Wiley
- Neanderthal-like ‘mini-brains’ created in lab with CRISPR – Nature.com
- Affordable CRISPR app reveals unintended mutations at site of CRISPR gene repair – Phys.org
- Affordable CRISPR app reveals unintended mutations at site of CRISPR gene repair – EurekAlert
- New CRISPR tech targets human genome’s complex code: Programmable CRISPR/Cas9-based kinase offers insights into, control over regulatory histone proteins – Science Daily
- After ditching Editas, AbbVie taps Caribou for new CRISPR, CAR-T pact – FierceBiotech
Leave a Reply
You must be logged in to post a comment.